The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list approaches its June 29 comment-window close. Once finalized, the rule effectively bars large-scale compounding of these GLP-1s under any clinical-need exception, accelerating the wind-down already underway among compounders (ProRx, BPI Labs, the Hims-affiliated manufacturer Medisource). Compounded GLP-1 telehealth platforms have largely pivoted to branded-drug fulfillment or microdose protocols, with the regulatory cliff at three weeks out.
Tuesday's Ozari Health launch at $86/month for compounded semaglutide and $120/month for compounded tirzepatide places the platform at the low end of the compounded GLP-1 telehealth pricing band. Comparable platforms in the same market: Sesame ~$99/month, Henry Meds $129-249/month, Wisp ~$199/month, Mochi Health $129/month introductory, MD Lifestyle $99-249/month. The pricing-floor compression is colliding with the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — comments close June 29, with the final determination expected late Q3 2026. If the FDA's 503B proposal stands, large-scale 503B compounding ends and platforms either shift to 503A pharmacies (lower volume, higher unit cost) or wind down. The current cohort of telehealth launches at $86-129/month likely represents the cheapest US compounded GLP-1 will be before the regulatory regime tightens. Branded Wegovy and Foundayo's $25-149/month commercial-insurance copays remain the lower-cost path for insured patients; the cash-pay compounded market is what these telehealth launches are competing for.